AskBio and Selecta Biosciences receive orphan drug designation for MMA-101 to treat methylmalonic acidemia

▴ AskBio and Selecta Biosciences receive orphan drug designation for MMA-101 to treat methylmalonic acidemia
AskBio and Selecta expect to initiate a Phase 1 clinical trial of MMA-101 and ImmTOR for patients with MMA in the first half of 2021

Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations. MMA-101 previously received rare pediatric disease designation from the FDA in October 2020.

“The orphan drug and rare pediatric disease designations for MMA-101 support the tremendous medical need that exists for patients with MMA,” said Sheila Mikhail, CEO and co-founder of AskBio. “We look forward to working with the FDA to bring a new treatment to these patients as efficiently and quickly as possible.”

“With ImmTOR in combination with AAV technology, Selecta and AskBio are seeking to address the significant unmet need in MMA. We’re pleased the FDA has further acknowledged these efforts by awarding the program orphan drug designation,” said Carsten Brunn, Ph.D., chief executive officer of Selecta Biosciences. “We are excited to continue evaluation of the ImmTOR platform to induce AAV-specific immune tolerance and potentially enable gene therapy redosing.”

MMA is a rare monogenic disorder in which the body cannot break down certain proteins and fats. This metabolic disease may lead to metabolic crisis and is associated with long-term complications, including feeding problems, developmental delays, intellectual impairment, chronic kidney disease, optic nerve atrophy, osteopenia and pancreatitis. Typically, well-managed patients have periods of relative health with intermittent metabolic decompensation events that may result in multiorgan failure, triggered by intercurrent infections or stress episodes. Symptoms of MMA usually appear in early infancy and vary from mild to life-threatening. Without treatment, this disorder can lead to coma and, in some cases, death.

AskBio and Selecta expect to initiate a Phase 1 clinical trial of MMA-101 and ImmTOR for patients with MMA in the first half of 2021.

The FDA Office of Orphan Products Development grants orphan drug designation to investigational treatments intended for rare diseases affecting fewer than 200,000 people in the U.S. The program was created to encourage the development of medicines for rare diseases, and benefits include tax credits and application fee waivers designed to offset some development costs, as well as eligibility for market exclusivity for seven years following approval.

The FDA grants rare pediatric disease designation to incentivize the development of new treatments for serious and life-threatening diseases that primarily affect children ages 18 years or younger, with fewer than 200,000 people affected in the U.S. The rare pediatric disease designation program allows sponsors who receive approval for a product to potentially qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product.

Tags : #AsklepiosBioPharmaceutical #LatestNewsonAskBio21stNov #SelectaBiosciences #LatestNewsonSelectaBiosciences21stNov #LatestPharmaNews21stNov #LatestPharmaCollaboration21stNov #LatestResearchonGeneTherapy #LatestUSFDAApproval21stNov #MonogenicDisorder

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Are we delivering new HIV prevention tools with speed, scale and equity?October 14, 2024
Hospital Lab Management: City Imaging & Clinical Labs to Expand Services to 50 Hospitals in North India by March 2027October 14, 2024
Women at Risk: India’s Breast Cancer Crisis and Its Impact on Future GenerationsOctober 14, 2024
Genetics or Lifestyle: Who’s Really to Blame for Your Premature Hair Loss?October 14, 2024
Decoding Parenthood: How Carrier Screening Can Shape a Healthier Future for India’s FamiliesOctober 14, 2024
Katrina Kaif Presents Kay Beauty’s Velvet Crème Blush: An iconic collectible multi-Use Magic blush in a revolutionary cushion crème-to-powder formulaOctober 11, 2024
Aakash Healthcare goes a step ahead: Movie Shows and Weekend Family Drives for doctors and nurses – Where work-life balance meets fun!October 11, 2024
Not Just a Day, But a Movement: The Real Impact of International Girl Child Day in IndiaOctober 11, 2024
From Darkness to Light: How India Wiped Out a Leading Cause of BlindnessOctober 11, 2024
India’s Diet Could Save the Planet: Why the World Needs to Follow Its Lead by 2050October 11, 2024
Is Your Brain Cleansing Itself? Discover the System That Could Save Your MindOctober 10, 2024
The Dark Side of Desire: How Personality Traits Influence Sexual BehaviorsOctober 10, 2024
India’s Mental Health Time Bomb: Can We Afford to Ignore It Any Longer?October 10, 2024
Go Cheese Announces Strategic Collaboration with Bigg Boss Season 18 to Enhance Brand Engagement and Consumer Reach Across IndiaOctober 10, 2024
DKMS BMST Foundation India Expands Stem Cell Donor Registry with 400+ New Donors registered from IIT DelhiOctober 10, 2024
FLAME University Launches the Centre for Research in Wellbeing and Happiness on International Day of Older PersonsOctober 10, 2024
Kaya Expands in Ludhiana with its 76th Clinic, Elevating Skincare with Advanced Wellness Solutions October 09, 2024
Dr Raj Nagarkar Becomes India’s 1st Oncologist on Cambridge Medical Robotics’ Advisory BoardOctober 09, 2024
Workplace Stress and Burnout Rate Reaching Critical Levels for Indian Employees, Warn ExpertsOctober 09, 2024
Are We Really Living Longer? The Surprising Reality of Life Expectancy TodayOctober 09, 2024